AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39513267 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination BNP/PDEV inhibition with sildenafil (25 mg q12 hours) for 48 hours
Number of subjects: 67
Study 39513267 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 67
Study 39513363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg p.o. daily with nivolumab 240 mg i.v. on days 1 and 15 of a 28-day cycle
Number of subjects: 16
Study 39513363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 16
Study 39513363 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 16
Study 39513369 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced skeletal muscle mass (sarcopenia)
Number of subjects: 2810
Study 39513369 — intervention group
Group type: COMPARATOR
Intervention: Preserved skeletal muscle mass
Number of subjects: 2810
Study 39513379 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39513382 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural products
Number of subjects: 0
Study 39513407 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG3970 350 mg + Sulfasalazine 1,000 mg
Number of subjects: 23
Study 39513407 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG3970 350 mg + Methotrexate 7.5 mg
Number of subjects: 23
Study 39513526 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab with or without prednisone
Number of subjects: 3720
Study 39513526 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 3720
Study 39513526 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab followed by MMF for 500 days
Number of subjects: 3720
Study 39513526 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF and levamisole
Number of subjects: 3720
Study 39513526 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 3720
Study 39513526 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 3720
Study 39513526 — intervention group
Group type: COMPARATOR
Intervention: Levamisole and prednisone
Number of subjects: 3720
Study 39513526 — intervention group
Group type: COMPARATOR
Intervention: Alkylating agents compared to cyclosporin
Number of subjects: 3720
Study 39513526 — intervention group
Group type: COMPARATOR
Intervention: Alkylating agents
Number of subjects: 3720
Study 39513526 — intervention group
Group type: COMPARATOR
Intervention: Alkylating agents compared to prednisone
Number of subjects: 3720
Study 39513569 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rhGH 0.2 mg/kg/week (high dose)
Number of subjects: 96
Study 39513569 — intervention group
Group type: COMPARATOR
Intervention: PEG-rhGH 0.1 mg/kg/week (low dose)
Number of subjects: 96
Study 39513754 — intervention group
Group type: EXPERIMENTAL
Intervention: Semorinemab
Number of subjects: 0
Study 39513970 — intervention group
Group type: EXPERIMENTAL
Intervention: LPCN 1148
Number of subjects: 29
Study 39513970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 39513971 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cTBS stimulation
Number of subjects: 44
Study 39513971 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 44
Study 39514000 — intervention group
Group type: EXPERIMENTAL
Intervention: DualRx (Acetazolamide + Eszopiclone)
Number of subjects: 20
Study 39514000 — intervention group
Group type: EXPERIMENTAL
Intervention: TripleRx (Acetazolamide + Eszopiclone + Venlafaxine)
Number of subjects: 20
Study 39514000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 39514025 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tamoxifen
Number of subjects: 824
Study 39514025 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg and 10 mg tamoxifen
Number of subjects: 824
Study 39514025 — intervention group
Group type: COMPARATOR
Intervention: Control group (postmenopausal women)
Number of subjects: 824
Study 39514027 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping the Noncompliant Child (HNC)
Number of subjects: 54
Study 39514041 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg subcutaneously every 4 weeks for 52 weeks
Number of subjects: 1059
Study 39514041 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 1059
Study 39514041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1059
Study 39514051 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (adjuvant therapy)
Number of subjects: 0
Study 39514051 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin with Tislelizumab (induction therapy)
Number of subjects: 0
Study 39514051 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor and CTLA4 inhibitor (anaplastic thyroid carcinoma)
Number of subjects: 0
Study 39514051 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR and VEGF inhibitors (intensification of dRCT in NPC)
Number of subjects: 0
Study 39514247 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based medication alerts for DOAC prescriptions
Number of subjects: 134
Study 39514254 — intervention group
Group type: EXPERIMENTAL
Intervention: KIM sling
Number of subjects: 147
Study 39514254 — intervention group
Group type: COMPARATOR
Intervention: TVT Exact sling
Number of subjects: 147
Study 39514256 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) group
Number of subjects: 9
Study 39514256 — intervention group
Group type: COMPARATOR
Intervention: Videoconference group
Number of subjects: 9
Study 39514264 — intervention group
Group type: EXPERIMENTAL
Intervention: VACT-CP
Number of subjects: 42
Study 39514264 — intervention group
Group type: COMPARATOR
Intervention: WL+TAU
Number of subjects: 42
Study 39514267 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg/m2) combined with chemotherapy and cryoablation
Number of subjects: 0
Study 39514431 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid cochlear implant with electric-acoustic stimulation (EAS)
Number of subjects: 52
Study 39514692 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-meat diet
Number of subjects: 36
Study 39514692 — intervention group
Group type: COMPARATOR
Intervention: Animal meat diet
Number of subjects: 36
Study 39514693 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid overload (any degree; >7%)
Number of subjects: 68196
Study 39514693 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid depletion (<−7%)
Number of subjects: 68196
Study 39514693 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyponatremia (sodium <135 mmol/L)
Number of subjects: 68196
Study 39514693 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypernatremia (sodium >145 mmol/L)
Number of subjects: 68196
Study 39514693 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dialysate sodium (≤138 mmol/L)
Number of subjects: 68196
Study 39514718 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention
Number of subjects: 143
Study 39514718 — intervention group
Group type: COMPARATOR
Intervention: Home safety control group
Number of subjects: 143
Study 39514718 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater variability in sleep onset timing
Number of subjects: 143
Study 39514718 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater variability in sleep midpoint timing
Number of subjects: 143
Study 39514777 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app-based self-management program (n = 25)
Number of subjects: 46
Study 39514777 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 46
Study 39514845 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV with active humidification
Number of subjects: 144
Study 39514845 — intervention group
Group type: COMPARATOR
Intervention: HFNC
Number of subjects: 144
Study 39514882 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions (MBIs)
Number of subjects: 708
Study 39514882 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 708
Study 39514895 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview (BNI) with cultural adaptations
Number of subjects: 132
Study 39514895 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated initiation of medications for AUD
Number of subjects: 132
Study 39514895 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based training for cognitive behavioral therapy (CBT4CBT)
Number of subjects: 132
Study 39514898 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid Overdose Education and Naloxone Distribution (OEND) training (n = 111)
Number of subjects: 304
Study 39514898 — intervention group
Group type: COMPARATOR
Intervention: Control group (those who declined training, n = 193)
Number of subjects: 304
Study 39515186 — intervention group
Group type: EXPERIMENTAL
Intervention: oVRcome mobile application (self-managed virtual reality exposure therapy combined with cognitive-behavioural techniques)
Number of subjects: 126
Study 39515186 — intervention group
Group type: COMPARATOR
Intervention: Waitlist delayed treatment group
Number of subjects: 126
Study 39515198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab-based regimen
Number of subjects: 35
Study 39515347 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorfenapyr-pyrethroid LLINs
Number of subjects: 19292
Study 39515347 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyriproxyfen-pyrethroid LLINs
Number of subjects: 19292
Study 39515347 — intervention group
Group type: COMPARATOR
Intervention: Pyrethroid only LLINs
Number of subjects: 19292
Study 39515361 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Management for Moms (PM4M) programme, a ten-session treatment offered by phone or in person.
Number of subjects: 265
Study 39515361 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Management for Moms (PM4M) programme
Number of subjects: 265
Study 39515361 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 265
Study 39515374 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy and the Equine Environment
Number of subjects: 0
Study 39515522 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 28
Study 39515522 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant eosinophil-lowering therapy
Number of subjects: 28
Study 39515580 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 73
Study 39515580 — intervention group
Group type: COMPARATOR
Intervention: Ultra-brief pulse right unilateral Electroconvulsive Therapy (ECT)
Number of subjects: 73
Study 39515756 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye-based diet
Number of subjects: 29
Study 39515845 — intervention group
Group type: EXPERIMENTAL
Intervention: Online exposure and response prevention behavioural therapy for tics
Number of subjects: 224
Study 39515845 — intervention group
Group type: COMPARATOR
Intervention: Online psychoeducation
Number of subjects: 224
Study 39515856 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual target transcranial magnetic stimulation (IT-TMS) combined with antidepressant medication
Number of subjects: 68
Study 39515856 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 68
Study 39515867 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 µg/kg/h after anaesthesia induction until dural closure, then 0.08 µg/kg/h for 48 hours postoperatively)
Number of subjects: 366
Study 39515867 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline, equal amounts of sufentanil and antiemetics, no dexmedetomidine)
Number of subjects: 366
Study 39515988 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% dextrose gel
Number of subjects: 169
Study 39515988 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 169
Study 39516087 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib
Number of subjects: 213
Study 39516087 — intervention group
Group type: COMPARATOR
Intervention: Ruxolitinib
Number of subjects: 213
Study 39516087 — intervention group
Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 213
Study 39516087 — intervention group
Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 213
Study 39516302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring electrodes (2 mm)
Number of subjects: 25
Study 39516302 — intervention group
Group type: COMPARATOR
Intervention: Tip- and mini-electrodes
Number of subjects: 25
Study 39516302 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance up to 4 mm
Number of subjects: 25
Study 39516302 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar electrograms with HF_rel above 10%
Number of subjects: 25
Study 39516358 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg (Q28) with vandetanib 300 mg od (f + v)
Number of subjects: 165
Study 39516358 — intervention group
Group type: COMPARATOR
Intervention: Placebo (f + p)
Number of subjects: 165
Study 39516358 — intervention group
Group type: EXPERIMENTAL
Intervention: High total RET expression
Number of subjects: 165
Study 39516370 — intervention group
Group type: EXPERIMENTAL
Intervention: E7389-LF 2.1 mg/m plus nivolumab
Number of subjects: 35
Study 39516454 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (150 mg, subcutaneous)
Number of subjects: 244
Study 39516456 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford Nanopore Technologies PromethION 2 solo system and Fabric GEM™ software
Number of subjects: 200
Study 39516456 — intervention group
Group type: COMPARATOR
Intervention: Clinically accredited short-read rapid genomic testing pipeline (Newborn Genomics Programme)
Number of subjects: 200
Study 39516524 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week web-based foot-ankle exercise program (SOPeD software) plus usual care
Number of subjects: 62
Study 39516524 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 62
Study 39516524 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week web-based foot-ankle exercise program (SOPeD software)
Number of subjects: 62
Study 39516558 — intervention group
Group type: EXPERIMENTAL
Intervention: IXA + BEV
Number of subjects: 76
Study 39516558 — intervention group
Group type: COMPARATOR
Intervention: IXA
Number of subjects: 76
Study 39516643 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 89
Study 39516643 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiomics-clinical signature
Number of subjects: 89
Study 39516643 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher radiomics score
Number of subjects: 89
Study 39516643 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics score
Number of subjects: 89
Study 39516643 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 89
Study 39516710 — intervention group
Group type: EXPERIMENTAL
Intervention: fampridine (10 mg twice daily for 3.5 days)
Number of subjects: 43
Study 39516710 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 43
Study 39516733 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual cups (one reusable disc-shaped menstrual cup per participant)
Number of subjects: 402
Study 39516806 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (IVR) intervention - watching ad-hoc videos showing Spanish regional landscapes and villages for approximately 4 minutes per day for three consecutive days.
Number of subjects: 212
Study 39516806 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent Physical Exercise (ME) intervention - aerobic and strength exercise for progressive training of the upper and lower limbs.
Number of subjects: 212
Study 39516806 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR + ME intervention - both cognitive and physical intervention.
Number of subjects: 212
Study 39516806 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - no specific intervention mentioned.
Number of subjects: 212
Study 39516806 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 212
Study 39516828 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate diet (VLC)
Number of subjects: 184
Study 39516828 — intervention group
Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 184
Study 39516844 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network-based intervention
Number of subjects: 0
Study 39516847 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-led home-based hypertension control program
Number of subjects: 1068
Study 39516847 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1068
Study 39516883 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in central venous-to-arterial PCO
Number of subjects: 205
Study 39516883 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔP(v-a)CO
Number of subjects: 205
Study 39517110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir (ATV/r) administered twice daily (BD)
Number of subjects: 0
Study 39517110 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted atazanavir (ATV/r) alone
Number of subjects: 0
Study 39517110 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin alone in pregnant women
Number of subjects: 0
Study 39518090 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Indicators in the Treatment of NMIBC
Number of subjects: 0
Study 39518689 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-Expandable Covered Stenting
Number of subjects: 0
Study 39519577 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 0
Study 39519577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39520048 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab-gxly
Number of subjects: 868
Study 39520048 — intervention group
Group type: COMPARATOR
Intervention: Dostarlimab-gxly with chemotherapy
Number of subjects: 868
Study 39520262 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday Problems Test (EPT)
Number of subjects: 0
Study 39520262 — intervention group
Group type: COMPARATOR
Intervention: Other IADL instruments
Number of subjects: 0
Study 39520455 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 6001
Study 39520455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6001
Study 39520501 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0
Study 39520501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39520516 — intervention group
Group type: EXPERIMENTAL
Intervention: PSFA-01 (dual-targeting tracer)
Number of subjects: 0
Study 39520516 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 39520605 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACON Caresystem advice on tidal volume/inspiratory pressure, inspired oxygen, respiratory rate and PEEP
Number of subjects: 112
Study 39520605 — intervention group
Group type: COMPARATOR
Intervention: Usual care (local clinical practice)
Number of subjects: 112
Study 39520630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 900
Study 39520630 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 900
Study 39520634 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg as needed up to once daily for up to 52 weeks
Number of subjects: 1800
Study 39520648 — intervention group
Group type: EXPERIMENTAL
Intervention: DB-macitentan patients (10 mg macitentan once-daily)
Number of subjects: 76
Study 39520648 — intervention group
Group type: COMPARATOR
Intervention: DB-placebo patients
Number of subjects: 76
Study 39520655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/day
Number of subjects: 1383
Study 39520655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3 mg/day
Number of subjects: 1383
Study 39520655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1383
Study 39520738 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 6
Study 39520893 — intervention group
Group type: EXPERIMENTAL
Intervention: MenABCWY
Number of subjects: 1379
Study 39520893 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-CRM (single dose)
Number of subjects: 1379
Study 39520893 — intervention group
Group type: EXPERIMENTAL
Intervention: MenB-fHbp
Number of subjects: 1379
Study 39520893 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose
Number of subjects: 1379
Study 39521008 — intervention group
Group type: EXPERIMENTAL
Intervention: Concizumab prophylaxis (1.0 mg/kg loading dose on day 1, followed by daily doses of 0.20 mg/kg, with options to adjust based on plasma concentration)
Number of subjects: 148
Study 39521008 — intervention group
Group type: EXPERIMENTAL
Intervention: Concizumab prophylaxis
Number of subjects: 148
Study 39521008 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (on-demand clotting factor)
Number of subjects: 148
Study 39521012 — intervention group
Group type: EXPERIMENTAL
Intervention: NmCV-5
Number of subjects: 1640
Study 39521012 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-D
Number of subjects: 1640
Study 39521094 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic background mucosal resurfacing (EBMR) with radiofrequency ablation (RFA)
Number of subjects: 30
Study 39521094 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic surveillance alone (control group)
Number of subjects: 30
Study 39521433 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 20 mg/kg every four weeks
Number of subjects: 669
Study 39521433 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy every three weeks for four to six cycles
Number of subjects: 669
Study 39521433 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 669
Study 39521433 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 669
Study 39521434 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Olaparib
Number of subjects: 672
Study 39521434 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab plus Pemetrexed
Number of subjects: 672
Study 39521460 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg buprenorphine maintenance daily dose
Number of subjects: 250
Study 39521460 — intervention group
Group type: COMPARATOR
Intervention: 16 mg buprenorphine maintenance daily dose
Number of subjects: 250